Current issues in oncology drug development, with a focus on phase ii trials

Journal of Biopharmaceutical Statistics

Volumn 19, Issue 3, 2009, Pages 556-562

  Sargent, Daniel J ^a   Taylor, Jeremy M G ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Efficient designs; Flexible adaptive designs; Phase I II trials; Randomized Phase II; Summarization of information

Indexed keywords

DRUG EFFICACY; DRUG SCREENING; MEDICAL SOCIETY; METHODOLOGY; NOTE; ONCOLOGY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRODUCTIVITY; PUBLICATION; RANDOMIZATION; STANDARD; ARTICLE; BIOASSAY; CHEMISTRY; DRUG DESIGN; HUMAN; RANDOMIZED CONTROLLED TRIAL; STATISTICS;

ANTINEOPLASTIC AGENT; TUMOR MARKER;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG DESIGN; ENDPOINT DETERMINATION; HUMANS; MEDICAL ONCOLOGY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TUMOR MARKERS, BIOLOGICAL;

EID: 67651061459     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543400902802474     Document Type: Note

References (27)

1. Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., Patterson, S. D., Chang, D. D. (2008). Wildtype KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(10):1626-1634.
2. Booth, C. M., Calvert, A. H., Giaccone, G., Lobbezoo, M. W., Eisenhauer, E. A., Seymour, L. K. (2008a). On behalf of the task force on methodology for the development of innovative cancer therapies. Design and conduct of Phase II studies of targeted anticancer therapy: Recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT). European J. Cancer 44:25-29.
3. Booth, C. M., Calvert, A. H., Giaccone, G., Lobbezoo, M. W., Seymour, L. K., Eisenhauer, E. A. (2008b). On behalf of the task force on methodology for the development of innovative cancer therapies. Endpoints and other considerations in Phase I studies of targeted anticancer therapies: Recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT). European J. Cancer 44:19-24.
4. Chen, C., Beckman, R. A. (2009). Optimal dose-effective designs of Phase II proof of concept trials and associated go-no go decisions. JBS.
5. Cheung, Y. K. (2009). Selecting promising treatments in randomized Phase II cancer trials with an active control. JBS.
6. Holford, N. H., Kimko, H. C., Monteleone, J. P., Peck, C. C. (2000). Simulation of clinical trials. Ann. Rev. Pharmacol. Toxicol. 40:209-234.
7. Jung, S.-H., George, S. L. (2009). Between-arm comparisons in randomized Phase II trials. JBS.
8. Kocherginsky, M., Cohen, E. E. W., Karrison, T. (2009). Design of Phase II cancer trials for evaluation of cytostatic/cytotoxic agents. JBS.
9. Liu, P. Y., LeBlanc, M., Desai, M. (1999). False positive rates in randomized Phase II designs. Contr. Clin. Trials 20:343-352.
10. Onar, A., Kocak, M., Boyett, J. M. (2009). Continual reassessment method vs. traditional empirically based design: Modifications motivated by Phase I trials in pediatric oncology by the pediatric brain tumor consortium. JBS.
11. O'Quigley, J., Zohar, S. (2006). Experimental designs for Phase I and Phase I/II dose-finding studies. Br. J. Cancer 94:609-613.
12. Ratain, M. J., Karrison, T. G. (2007). Testing the wrong hypothesis in Phase II oncology trials: There is a better alternative. Clin. Cancer Res. 13(3):781-782.
13. Ratain, M. J., Sargent, D. J. (2009). Optimising the design of Phase II oncology trials: The importance of randomization. European J. Cancer 45:275-280.
14. Redman, M., Crowley, J. (2007). Small randomized trials. J. Thorac. Oncol. 2(1):1-2.
15. Rogatko, A., Schoeneck, D., Jonas, W., Tighiouart, M., Khuri, F. R., Porter, A. (2007). Translation of innovative designs into Phase I trials. J. Clin. Oncol. 25(31): 4982-4986.
16. Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E. Jr., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., Swain, S. M., Pisansky, T. M., Fehrenbacher, L., Kutteh, L. A., Vogel, V. G., Visscher, D. W., Yothers, G., Jenkins, R. B., Brown, A. M., Dakhil, S. R., Mamounas, E. P., Lingle, W. L., Klein, P. M., Ingle, J. N., Wolmark, N. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353(16):1673-1684.
17. Rubenstein, L. V., Korn, E. L., Freidlin, B., Hunsberger, S., Ivy, S. P., Smith, M. A. (2005). Design issues of randomized Phase II trials and a proposal for Phase II screening trials. J. Clin. Oncol. 23(28):7199-7206.
18. Sargent, D. J., Goldberg, R. M. (2001). A flexible design for multiple armed screening trials. Stat. Med. 20(7):1051-1060.
19. Simon, R., Wittes, R. E., Ellenberg, S. S. (1985). Randomized Phase II clinical trials. Cancer Treat Rep. 69(12):1375-1381.
20. Simon, R., Thall, P. F., Ellenberg, S. S. (1994). New designs for the selection of treatments to be tested in randomized clinical trials. Stat. Med. 13(5-7):417-429.
21. Sun, L. Z., Chen, C., Patel, K. (2009). Optimal two-stage randomized multinomial designs for Phase II oncology trials. JBS.
22. Taylor, J. M. G., Braun, T., Li, Z. (2006). Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design. Clinical Trials (4):335-348.
23. Thall, P. F., Simon, R. (1994). Practical Bayesian guidelines for Phase IIB clinical trials. Biometrics 50(2):337-349.
24. Thall, P. F., Estey, E. H. (2005). Some ethical issues in Phase II trials in acute leukemia. Clinical Advances Hem. & Onc. 3(12):943-948.
25. Vickers, A. J., Ballen, V., Scher, H. I. (2007). Setting the bar in Phase II trials: The use of historical data for determining "go/no go" decision for definitive Phase III testing. Clin. Cancer Res. 13(3):792-796.
26. Wieand, H. S. (2005). Randomized Phase II trials: What does randomization gain? J. Clin. Oncol. 23(9):1794-1795.
27. Zohar, S., Chevret, S. (2007). Recent developments in adaptive designs for Phase I/II dosefinding studies. J. Biopharm. Stat. 17(6):1071-1083.